Table 1 Demographic data and baseline characteristics
|  | Budesonide (N = 103) | Placebo (N = 103) |
|---|---|---|
Age (years) | 35.2 ± 10.03 | 36.9 ± 11.12 |
Sex (male) | 50 (48.5%) | 55 (53.4%) |
BMI (kg/m2) | 23.33 ± 3.47 | 23.96 ± 3.45 |
Outdoor exposure (hours) | ||
 1–6 | 95 (92.2%) | 92 (89.3%) |
 > 6, ≤ 8 | 5 (4.9%) | 3 (2.9%) |
 > 8 | 3 (2.9%) | 8 (7.8%) |
Daily AQI exposure | 110.2 (53.1 to 230.8) | 111.6 (59.7 to 230.8) |
Baseline rTNSS | 6.8 ± 1.27 | 7.1 ± 1.04 |
Nasal symptom scores | ||
 NO | 2.5 ± 0.78 | 2.4 ± 0.72 |
 Secretion/RN | 2.4 ± 0.74 | 2.5 ± 0.67 |
 Itching/SN | 1.9 ± 0.80 | 2.1 ± 0.74 |
Non-nasal symptom scores | ||
 Cough | 0.88 ± 0.97 | 0.92 ± 0.93 |
 Postnasal drip | 1.61 ± 0.92 | 1.56 ± 1.00 |
Duration of treatment (days) | 11.0 (3.0 to 12.0) | 12.0 (6.0 to 12.0) |
Allergy medical history | 17 (16.5%) | 13 (12.6%) |
Hypertension | 1 (1.0%) | 1 (1.0%) |
Diabetes | 1 (1.0%) | 0 |